NASDAQ:MRSNMersana Therapeutics Stock Price, Forecast & News

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN shares have increased by 250.5% and is now trading at $22.64. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mersana Therapeutics.

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Mersana Therapeutics.

Mersana Therapeutics Inc (NASDAQ:MRSN) announced its earnings results on Friday, May, 8th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. The company earned $0.01 million during the quarter, compared to analysts' expectations of $0.37 million. Mersana Therapeutics had a negative net margin of 6,099.64% and a negative return on equity of 78.18%. View Mersana Therapeutics' earnings history.

5 brokers have issued 12-month price targets for Mersana Therapeutics' stock. Their forecasts range from $14.00 to $26.00. On average, they expect Mersana Therapeutics' stock price to reach $20.25 in the next twelve months. This suggests that the stock has a possible downside of 10.6%. View analysts' price targets for Mersana Therapeutics.

Media coverage about MRSN stock has trended somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mersana Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutMersana Therapeutics.

Some companies that are related to Mersana Therapeutics include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), PPD (SDGR), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Nektar Therapeutics (NKTR), ChemoCentryx (CCXI), GW Pharmaceuticals PLC- (GWPH) and Biohaven Pharmaceutical (BHVN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Amarin (AMRN), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Marinus Pharmaceuticals (MRNS), ImmunoGen (IMGN), vTv Therapeutics (VTVT), Advanced Micro Devices (AMD) and Clovis Oncology (CLVS).

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.58%), VR Adviser LLC (4.45%), Ghost Tree Capital LLC (3.39%), Orbimed Advisors LLC (2.28%), State Street Corp (1.18%) and JPMorgan Chase & Co. (0.76%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Enterprise Associates 14 New, Scott D Sandell and Timothy B Lowinger. View institutional ownership trends for Mersana Therapeutics.

MRSN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, JPMorgan Chase & Co., Morgan Stanley, UBS Group AG, Legal & General Group Plc, and American International Group Inc.. View insider buying and selling activity for Mersana Therapeutics.

MRSN stock was acquired by a variety of institutional investors in the last quarter, including VR Adviser LLC, Ghost Tree Capital LLC, BlackRock Inc., AXA, DAFNA Capital Management LLC, Sofinnova Investments Inc., Bailard Inc., and Mackenzie Financial Corp. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Enterprise Associates 14 New. View insider buying and selling activity for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $22.64.

Mersana Therapeutics has a market capitalization of $1.33 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.

The official website for Mersana Therapeutics is www.mersana.com.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]